argenx hits first operating profit as VYVGART sales surpass $4B
Compartilhar
Immunology pioneer argenx (NASDAQ:ARGX) delivered its first-ever year of operating profitability in 2025, powered by a massive commercial expansion of its flagship FcRn blocker, VYVGART.
